Combination	B:C0013162
of	O
telmisartan	O
with	O
sildenafil	O
ameliorate	O
progression	O
of	O
diabetic	O
nephropathy	I:C0011881
in	O
streptozotocin	O
-	O
induced	O
diabetic	O
model	O
.	O

Combination	O
of	O
telmisartan	B:C0248719
with	O
sildenafil	O
ameliorate	O
progression	O
of	O
diabetic	O
nephropathy	I:C0011881
in	O
streptozotocin	O
-	O
induced	O
diabetic	O
model	O
.	O

Combination	O
of	O
telmisartan	O
with	O
sildenafil	B:C0529793
ameliorate	O
progression	O
of	O
diabetic	O
nephropathy	I:C0011881
in	O
streptozotocin	O
-	O
induced	O
diabetic	O
model	O
.	O

Combination	O
of	O
telmisartan	O
with	O
sildenafil	O
ameliorate	O
progression	B:C0242656
of	O
diabetic	O
nephropathy	I:C0011881
in	O
streptozotocin	O
-	O
induced	O
diabetic	O
model	O
.	O

Combination	O
of	O
telmisartan	O
with	O
sildenafil	O
ameliorate	O
progression	O
of	O
diabetic	B:C0011881
nephropathy	I:C0011881
in	O
streptozotocin	O
-	O
induced	O
diabetic	O
model	O
.	O

Combination	O
of	O
telmisartan	O
with	O
sildenafil	O
ameliorate	O
progression	O
of	O
diabetic	O
nephropathy	I:C0011881
in	O
streptozotocin	B:C0038432
-	O
induced	O
diabetic	O
model	O
.	O

Combination	O
of	O
telmisartan	O
with	O
sildenafil	O
ameliorate	O
progression	O
of	O
diabetic	O
nephropathy	I:C0011881
in	O
streptozotocin	O
-	O
induced	O
diabetic	B:C0241863
model	O
.	O

Diabetic	B:C0011881
nephropathy	I:C0011881
(	O
Diabetic	O
nephropathy	I:C0011881
)	O
is	O
a	O
leading	O
cause	O
of	O
end	O
-	I:C0022661
stage	I:C0022661
renal	I:C0022661
disease	I:C0022661
in	O
the	O
world	O
.	O

Diabetic	O
nephropathy	I:C0011881
(	O
Diabetic	B:C0011881
nephropathy	I:C0011881
)	O
is	O
a	O
leading	O
cause	O
of	O
end	O
-	I:C0022661
stage	I:C0022661
renal	I:C0022661
disease	I:C0022661
in	O
the	O
world	O
.	O

Diabetic	O
nephropathy	I:C0011881
(	O
Diabetic	O
nephropathy	I:C0011881
)	O
is	O
a	O
leading	O
cause	O
of	O
end	B:C0022661
-	I:C0022661
stage	I:C0022661
renal	I:C0022661
disease	I:C0022661
in	O
the	O
world	O
.	O

Several	O
signaling	B:C0037080
pathways	I:C0037080
are	O
involved	O
in	O
the	O
pathogenesis	O
of	O
Diabetic	O
nephropathy	I:C0011881
including	O
elevation	O
in	O
level	O
of	O
angiotensin	O
II	I:C0003009
,	O
formation	O
of	O
advanced	O
glycation	I:C0162574
end	I:C0162574
products	I:C0162574
(	O
advanced	O
glycation	I:C0162574
end	I:C0162574
products	I:C0162574
)	O
,	O
activation	O
of	O
protein	O
kinase	I:C0033634
c	I:C0033634
(	O
protein	O
kinase	I:C0033634
c	I:C0033634
)	O
,	O
and	O
lipid	O
accumulation	I:C0333574
.	O

Several	O
signaling	O
pathways	I:C0037080
are	O
involved	O
in	O
the	O
pathogenesis	B:C0699748
of	O
Diabetic	O
nephropathy	I:C0011881
including	O
elevation	O
in	O
level	O
of	O
angiotensin	O
II	I:C0003009
,	O
formation	O
of	O
advanced	O
glycation	I:C0162574
end	I:C0162574
products	I:C0162574
(	O
advanced	O
glycation	I:C0162574
end	I:C0162574
products	I:C0162574
)	O
,	O
activation	O
of	O
protein	O
kinase	I:C0033634
c	I:C0033634
(	O
protein	O
kinase	I:C0033634
c	I:C0033634
)	O
,	O
and	O
lipid	O
accumulation	I:C0333574
.	O

Several	O
signaling	O
pathways	I:C0037080
are	O
involved	O
in	O
the	O
pathogenesis	O
of	O
Diabetic	B:C0011881
nephropathy	I:C0011881
including	O
elevation	O
in	O
level	O
of	O
angiotensin	O
II	I:C0003009
,	O
formation	O
of	O
advanced	O
glycation	I:C0162574
end	I:C0162574
products	I:C0162574
(	O
advanced	O
glycation	I:C0162574
end	I:C0162574
products	I:C0162574
)	O
,	O
activation	O
of	O
protein	O
kinase	I:C0033634
c	I:C0033634
(	O
protein	O
kinase	I:C0033634
c	I:C0033634
)	O
,	O
and	O
lipid	O
accumulation	I:C0333574
.	O

Several	O
signaling	O
pathways	I:C0037080
are	O
involved	O
in	O
the	O
pathogenesis	O
of	O
Diabetic	O
nephropathy	I:C0011881
including	O
elevation	B:C0702240
in	O
level	O
of	O
angiotensin	O
II	I:C0003009
,	O
formation	O
of	O
advanced	O
glycation	I:C0162574
end	I:C0162574
products	I:C0162574
(	O
advanced	O
glycation	I:C0162574
end	I:C0162574
products	I:C0162574
)	O
,	O
activation	O
of	O
protein	O
kinase	I:C0033634
c	I:C0033634
(	O
protein	O
kinase	I:C0033634
c	I:C0033634
)	O
,	O
and	O
lipid	O
accumulation	I:C0333574
.	O

Several	O
signaling	O
pathways	I:C0037080
are	O
involved	O
in	O
the	O
pathogenesis	O
of	O
Diabetic	O
nephropathy	I:C0011881
including	O
elevation	O
in	O
level	O
of	O
angiotensin	B:C0003009
II	I:C0003009
,	O
formation	O
of	O
advanced	O
glycation	I:C0162574
end	I:C0162574
products	I:C0162574
(	O
advanced	O
glycation	I:C0162574
end	I:C0162574
products	I:C0162574
)	O
,	O
activation	O
of	O
protein	O
kinase	I:C0033634
c	I:C0033634
(	O
protein	O
kinase	I:C0033634
c	I:C0033634
)	O
,	O
and	O
lipid	O
accumulation	I:C0333574
.	O

Several	O
signaling	O
pathways	I:C0037080
are	O
involved	O
in	O
the	O
pathogenesis	O
of	O
Diabetic	O
nephropathy	I:C0011881
including	O
elevation	O
in	O
level	O
of	O
angiotensin	O
II	I:C0003009
,	O
formation	O
of	O
advanced	B:C0162574
glycation	I:C0162574
end	I:C0162574
products	I:C0162574
(	O
advanced	O
glycation	I:C0162574
end	I:C0162574
products	I:C0162574
)	O
,	O
activation	O
of	O
protein	O
kinase	I:C0033634
c	I:C0033634
(	O
protein	O
kinase	I:C0033634
c	I:C0033634
)	O
,	O
and	O
lipid	O
accumulation	I:C0333574
.	O

Several	O
signaling	O
pathways	I:C0037080
are	O
involved	O
in	O
the	O
pathogenesis	O
of	O
Diabetic	O
nephropathy	I:C0011881
including	O
elevation	O
in	O
level	O
of	O
angiotensin	O
II	I:C0003009
,	O
formation	O
of	O
advanced	O
glycation	I:C0162574
end	I:C0162574
products	I:C0162574
(	O
advanced	B:C0162574
glycation	I:C0162574
end	I:C0162574
products	I:C0162574
)	O
,	O
activation	O
of	O
protein	O
kinase	I:C0033634
c	I:C0033634
(	O
protein	O
kinase	I:C0033634
c	I:C0033634
)	O
,	O
and	O
lipid	O
accumulation	I:C0333574
.	O

Several	O
signaling	O
pathways	I:C0037080
are	O
involved	O
in	O
the	O
pathogenesis	O
of	O
Diabetic	O
nephropathy	I:C0011881
including	O
elevation	O
in	O
level	O
of	O
angiotensin	O
II	I:C0003009
,	O
formation	O
of	O
advanced	O
glycation	I:C0162574
end	I:C0162574
products	I:C0162574
(	O
advanced	O
glycation	I:C0162574
end	I:C0162574
products	I:C0162574
)	O
,	O
activation	B:C1819041
of	O
protein	O
kinase	I:C0033634
c	I:C0033634
(	O
protein	O
kinase	I:C0033634
c	I:C0033634
)	O
,	O
and	O
lipid	O
accumulation	I:C0333574
.	O

Several	O
signaling	O
pathways	I:C0037080
are	O
involved	O
in	O
the	O
pathogenesis	O
of	O
Diabetic	O
nephropathy	I:C0011881
including	O
elevation	O
in	O
level	O
of	O
angiotensin	O
II	I:C0003009
,	O
formation	O
of	O
advanced	O
glycation	I:C0162574
end	I:C0162574
products	I:C0162574
(	O
advanced	O
glycation	I:C0162574
end	I:C0162574
products	I:C0162574
)	O
,	O
activation	O
of	O
protein	B:C0033634
kinase	I:C0033634
c	I:C0033634
(	O
protein	O
kinase	I:C0033634
c	I:C0033634
)	O
,	O
and	O
lipid	O
accumulation	I:C0333574
.	O

Several	O
signaling	O
pathways	I:C0037080
are	O
involved	O
in	O
the	O
pathogenesis	O
of	O
Diabetic	O
nephropathy	I:C0011881
including	O
elevation	O
in	O
level	O
of	O
angiotensin	O
II	I:C0003009
,	O
formation	O
of	O
advanced	O
glycation	I:C0162574
end	I:C0162574
products	I:C0162574
(	O
advanced	O
glycation	I:C0162574
end	I:C0162574
products	I:C0162574
)	O
,	O
activation	O
of	O
protein	O
kinase	I:C0033634
c	I:C0033634
(	O
protein	B:C0033634
kinase	I:C0033634
c	I:C0033634
)	O
,	O
and	O
lipid	O
accumulation	I:C0333574
.	O

Several	O
signaling	O
pathways	I:C0037080
are	O
involved	O
in	O
the	O
pathogenesis	O
of	O
Diabetic	O
nephropathy	I:C0011881
including	O
elevation	O
in	O
level	O
of	O
angiotensin	O
II	I:C0003009
,	O
formation	O
of	O
advanced	O
glycation	I:C0162574
end	I:C0162574
products	I:C0162574
(	O
advanced	O
glycation	I:C0162574
end	I:C0162574
products	I:C0162574
)	O
,	O
activation	O
of	O
protein	O
kinase	I:C0033634
c	I:C0033634
(	O
protein	O
kinase	I:C0033634
c	I:C0033634
)	O
,	O
and	O
lipid	B:C0333574
accumulation	I:C0333574
.	O

These	O
pathways	B:C0037080
activate	O
one	O
another	O
mutually	O
leading	O
to	O
oxidative	O
stress	I:C0242606
,	O
increasing	O
expression	O
of	O
transforming	O
growth	I:C1704256
factor	I:C1704256
beta	I:C1704256
-	I:C1704256
1	I:C1704256
(	O
transforming	O
growth	I:C1704256
factor	I:C1704256
beta	I:C1704256
-	I:C1704256
1	I:C1704256
)	O
and	O
release	O
of	O
interleukins	O
and	O
adhesion	O
molecules	I:C0007578
,	O
so	O
the	O
aim	O
of	O
this	O
study	O
is	O
to	O
interrupt	O
more	O
than	O
pathogenic	O
pathway	O
to	O
ameliorate	O
the	O
progression	O
of	O
Diabetic	O
nephropathy	I:C0011881
.	O

These	O
pathways	O
activate	O
one	O
another	O
mutually	O
leading	O
to	O
oxidative	B:C0242606
stress	I:C0242606
,	O
increasing	O
expression	O
of	O
transforming	O
growth	I:C1704256
factor	I:C1704256
beta	I:C1704256
-	I:C1704256
1	I:C1704256
(	O
transforming	O
growth	I:C1704256
factor	I:C1704256
beta	I:C1704256
-	I:C1704256
1	I:C1704256
)	O
and	O
release	O
of	O
interleukins	O
and	O
adhesion	O
molecules	I:C0007578
,	O
so	O
the	O
aim	O
of	O
this	O
study	O
is	O
to	O
interrupt	O
more	O
than	O
pathogenic	O
pathway	O
to	O
ameliorate	O
the	O
progression	O
of	O
Diabetic	O
nephropathy	I:C0011881
.	O

These	O
pathways	O
activate	O
one	O
another	O
mutually	O
leading	O
to	O
oxidative	O
stress	I:C0242606
,	O
increasing	O
expression	B:C1171362
of	O
transforming	O
growth	I:C1704256
factor	I:C1704256
beta	I:C1704256
-	I:C1704256
1	I:C1704256
(	O
transforming	O
growth	I:C1704256
factor	I:C1704256
beta	I:C1704256
-	I:C1704256
1	I:C1704256
)	O
and	O
release	O
of	O
interleukins	O
and	O
adhesion	O
molecules	I:C0007578
,	O
so	O
the	O
aim	O
of	O
this	O
study	O
is	O
to	O
interrupt	O
more	O
than	O
pathogenic	O
pathway	O
to	O
ameliorate	O
the	O
progression	O
of	O
Diabetic	O
nephropathy	I:C0011881
.	O

These	O
pathways	O
activate	O
one	O
another	O
mutually	O
leading	O
to	O
oxidative	O
stress	I:C0242606
,	O
increasing	O
expression	O
of	O
transforming	B:C1704256
growth	I:C1704256
factor	I:C1704256
beta	I:C1704256
-	I:C1704256
1	I:C1704256
(	O
transforming	O
growth	I:C1704256
factor	I:C1704256
beta	I:C1704256
-	I:C1704256
1	I:C1704256
)	O
and	O
release	O
of	O
interleukins	O
and	O
adhesion	O
molecules	I:C0007578
,	O
so	O
the	O
aim	O
of	O
this	O
study	O
is	O
to	O
interrupt	O
more	O
than	O
pathogenic	O
pathway	O
to	O
ameliorate	O
the	O
progression	O
of	O
Diabetic	O
nephropathy	I:C0011881
.	O

These	O
pathways	O
activate	O
one	O
another	O
mutually	O
leading	O
to	O
oxidative	O
stress	I:C0242606
,	O
increasing	O
expression	O
of	O
transforming	O
growth	I:C1704256
factor	I:C1704256
beta	I:C1704256
-	I:C1704256
1	I:C1704256
(	O
transforming	B:C1704256
growth	I:C1704256
factor	I:C1704256
beta	I:C1704256
-	I:C1704256
1	I:C1704256
)	O
and	O
release	O
of	O
interleukins	O
and	O
adhesion	O
molecules	I:C0007578
,	O
so	O
the	O
aim	O
of	O
this	O
study	O
is	O
to	O
interrupt	O
more	O
than	O
pathogenic	O
pathway	O
to	O
ameliorate	O
the	O
progression	O
of	O
Diabetic	O
nephropathy	I:C0011881
.	O

These	O
pathways	O
activate	O
one	O
another	O
mutually	O
leading	O
to	O
oxidative	O
stress	I:C0242606
,	O
increasing	O
expression	O
of	O
transforming	O
growth	I:C1704256
factor	I:C1704256
beta	I:C1704256
-	I:C1704256
1	I:C1704256
(	O
transforming	O
growth	I:C1704256
factor	I:C1704256
beta	I:C1704256
-	I:C1704256
1	I:C1704256
)	O
and	O
release	O
of	O
interleukins	B:C0021764
and	O
adhesion	O
molecules	I:C0007578
,	O
so	O
the	O
aim	O
of	O
this	O
study	O
is	O
to	O
interrupt	O
more	O
than	O
pathogenic	O
pathway	O
to	O
ameliorate	O
the	O
progression	O
of	O
Diabetic	O
nephropathy	I:C0011881
.	O

These	O
pathways	O
activate	O
one	O
another	O
mutually	O
leading	O
to	O
oxidative	O
stress	I:C0242606
,	O
increasing	O
expression	O
of	O
transforming	O
growth	I:C1704256
factor	I:C1704256
beta	I:C1704256
-	I:C1704256
1	I:C1704256
(	O
transforming	O
growth	I:C1704256
factor	I:C1704256
beta	I:C1704256
-	I:C1704256
1	I:C1704256
)	O
and	O
release	O
of	O
interleukins	O
and	O
adhesion	B:C0007578
molecules	I:C0007578
,	O
so	O
the	O
aim	O
of	O
this	O
study	O
is	O
to	O
interrupt	O
more	O
than	O
pathogenic	O
pathway	O
to	O
ameliorate	O
the	O
progression	O
of	O
Diabetic	O
nephropathy	I:C0011881
.	O

These	O
pathways	O
activate	O
one	O
another	O
mutually	O
leading	O
to	O
oxidative	O
stress	I:C0242606
,	O
increasing	O
expression	O
of	O
transforming	O
growth	I:C1704256
factor	I:C1704256
beta	I:C1704256
-	I:C1704256
1	I:C1704256
(	O
transforming	O
growth	I:C1704256
factor	I:C1704256
beta	I:C1704256
-	I:C1704256
1	I:C1704256
)	O
and	O
release	O
of	O
interleukins	O
and	O
adhesion	O
molecules	I:C0007578
,	O
so	O
the	O
aim	O
of	O
this	O
study	O
is	O
to	O
interrupt	O
more	O
than	O
pathogenic	B:C3816499
pathway	O
to	O
ameliorate	O
the	O
progression	O
of	O
Diabetic	O
nephropathy	I:C0011881
.	O

These	O
pathways	O
activate	O
one	O
another	O
mutually	O
leading	O
to	O
oxidative	O
stress	I:C0242606
,	O
increasing	O
expression	O
of	O
transforming	O
growth	I:C1704256
factor	I:C1704256
beta	I:C1704256
-	I:C1704256
1	I:C1704256
(	O
transforming	O
growth	I:C1704256
factor	I:C1704256
beta	I:C1704256
-	I:C1704256
1	I:C1704256
)	O
and	O
release	O
of	O
interleukins	O
and	O
adhesion	O
molecules	I:C0007578
,	O
so	O
the	O
aim	O
of	O
this	O
study	O
is	O
to	O
interrupt	O
more	O
than	O
pathogenic	O
pathway	O
to	O
ameliorate	O
the	O
progression	B:C0242656
of	O
Diabetic	O
nephropathy	I:C0011881
.	O

These	O
pathways	O
activate	O
one	O
another	O
mutually	O
leading	O
to	O
oxidative	O
stress	I:C0242606
,	O
increasing	O
expression	O
of	O
transforming	O
growth	I:C1704256
factor	I:C1704256
beta	I:C1704256
-	I:C1704256
1	I:C1704256
(	O
transforming	O
growth	I:C1704256
factor	I:C1704256
beta	I:C1704256
-	I:C1704256
1	I:C1704256
)	O
and	O
release	O
of	O
interleukins	O
and	O
adhesion	O
molecules	I:C0007578
,	O
so	O
the	O
aim	O
of	O
this	O
study	O
is	O
to	O
interrupt	O
more	O
than	O
pathogenic	O
pathway	O
to	O
ameliorate	O
the	O
progression	O
of	O
Diabetic	B:C0011881
nephropathy	I:C0011881
.	O

In	O
the	O
present	O
study	B:C0008972
,	O
white	O
male	O
rats	O
(	O
N=48	O
)	O
were	O
divided	O
into	O
six	O
groups	O
(	O
8	O
rats	O
each	O
)	O
,	O
the	O
first	O
two	O
groups	O
served	O
as	O
normal	O
control	O
and	O
a	O
control	O
vehicle	O
group	O
while	O
the	O
remaining	O
four	O
groups	O
were	O
rendered	O
diabetic	O
by	O
a	O
single	O
intraperitoneal	O
injection	I:C0021493
of	O
Streptozotocin	O
(	O
Streptozotocin	O
)	O
and	O
being	O
left	O
for	O
4	O
weeks	O
to	O
develop	O
Diabetic	O
nephropathy	I:C0011881
.	O

In	O
the	O
present	O
study	O
,	O
white	O
male	O
rats	O
(	O
N=48	O
)	O
were	O
divided	O
into	O
six	O
groups	O
(	O
8	O
rats	O
each	O
)	O
,	O
the	O
first	O
two	O
groups	O
served	O
as	O
normal	O
control	O
and	O
a	O
control	O
vehicle	O
group	O
while	O
the	O
remaining	O
four	O
groups	O
were	O
rendered	O
diabetic	B:C0241863
by	O
a	O
single	O
intraperitoneal	O
injection	I:C0021493
of	O
Streptozotocin	O
(	O
Streptozotocin	O
)	O
and	O
being	O
left	O
for	O
4	O
weeks	O
to	O
develop	O
Diabetic	O
nephropathy	I:C0011881
.	O

In	O
the	O
present	O
study	O
,	O
white	O
male	O
rats	O
(	O
N=48	O
)	O
were	O
divided	O
into	O
six	O
groups	O
(	O
8	O
rats	O
each	O
)	O
,	O
the	O
first	O
two	O
groups	O
served	O
as	O
normal	O
control	O
and	O
a	O
control	O
vehicle	O
group	O
while	O
the	O
remaining	O
four	O
groups	O
were	O
rendered	O
diabetic	O
by	O
a	O
single	O
intraperitoneal	B:C0021493
injection	I:C0021493
of	O
Streptozotocin	O
(	O
Streptozotocin	O
)	O
and	O
being	O
left	O
for	O
4	O
weeks	O
to	O
develop	O
Diabetic	O
nephropathy	I:C0011881
.	O

In	O
the	O
present	O
study	O
,	O
white	O
male	O
rats	O
(	O
N=48	O
)	O
were	O
divided	O
into	O
six	O
groups	O
(	O
8	O
rats	O
each	O
)	O
,	O
the	O
first	O
two	O
groups	O
served	O
as	O
normal	O
control	O
and	O
a	O
control	O
vehicle	O
group	O
while	O
the	O
remaining	O
four	O
groups	O
were	O
rendered	O
diabetic	O
by	O
a	O
single	O
intraperitoneal	O
injection	I:C0021493
of	O
Streptozotocin	B:C0038432
(	O
Streptozotocin	O
)	O
and	O
being	O
left	O
for	O
4	O
weeks	O
to	O
develop	O
Diabetic	O
nephropathy	I:C0011881
.	O

In	O
the	O
present	O
study	O
,	O
white	O
male	O
rats	O
(	O
N=48	O
)	O
were	O
divided	O
into	O
six	O
groups	O
(	O
8	O
rats	O
each	O
)	O
,	O
the	O
first	O
two	O
groups	O
served	O
as	O
normal	O
control	O
and	O
a	O
control	O
vehicle	O
group	O
while	O
the	O
remaining	O
four	O
groups	O
were	O
rendered	O
diabetic	O
by	O
a	O
single	O
intraperitoneal	O
injection	I:C0021493
of	O
Streptozotocin	O
(	O
Streptozotocin	B:C0038432
)	O
and	O
being	O
left	O
for	O
4	O
weeks	O
to	O
develop	O
Diabetic	O
nephropathy	I:C0011881
.	O

In	O
the	O
present	O
study	O
,	O
white	O
male	O
rats	O
(	O
N=48	O
)	O
were	O
divided	O
into	O
six	O
groups	O
(	O
8	O
rats	O
each	O
)	O
,	O
the	O
first	O
two	O
groups	O
served	O
as	O
normal	O
control	O
and	O
a	O
control	O
vehicle	O
group	O
while	O
the	O
remaining	O
four	O
groups	O
were	O
rendered	O
diabetic	O
by	O
a	O
single	O
intraperitoneal	O
injection	I:C0021493
of	O
Streptozotocin	O
(	O
Streptozotocin	O
)	O
and	O
being	O
left	O
for	O
4	O
weeks	O
to	O
develop	O
Diabetic	B:C0011881
nephropathy	I:C0011881
.	O

Thereafter	O
,	O
the	O
rats	O
were	O
divided	O
into	O
Diabetic	B:C0011881
nephropathy	I:C0011881
group	O
,	O
Diabetic	O
nephropathy	I:C0011881
group	O
receiving	O
Telmisartan	O
or	O
Sildenafil	O
or	O
Telmisartan	O
Sildenafil	O
combination	O
.	O

Thereafter	O
,	O
the	O
rats	O
were	O
divided	O
into	O
Diabetic	O
nephropathy	I:C0011881
group	O
,	O
Diabetic	B:C0011881
nephropathy	I:C0011881
group	O
receiving	O
Telmisartan	O
or	O
Sildenafil	O
or	O
Telmisartan	O
Sildenafil	O
combination	O
.	O

Thereafter	O
,	O
the	O
rats	O
were	O
divided	O
into	O
Diabetic	O
nephropathy	I:C0011881
group	O
,	O
Diabetic	O
nephropathy	I:C0011881
group	O
receiving	O
Telmisartan	B:C0248719
or	O
Sildenafil	O
or	O
Telmisartan	O
Sildenafil	O
combination	O
.	O

Thereafter	O
,	O
the	O
rats	O
were	O
divided	O
into	O
Diabetic	O
nephropathy	I:C0011881
group	O
,	O
Diabetic	O
nephropathy	I:C0011881
group	O
receiving	O
Telmisartan	O
or	O
Sildenafil	B:C0529793
or	O
Telmisartan	O
Sildenafil	O
combination	O
.	O

Thereafter	O
,	O
the	O
rats	O
were	O
divided	O
into	O
Diabetic	O
nephropathy	I:C0011881
group	O
,	O
Diabetic	O
nephropathy	I:C0011881
group	O
receiving	O
Telmisartan	O
or	O
Sildenafil	O
or	O
Telmisartan	B:C0248719
Sildenafil	O
combination	O
.	O

Thereafter	O
,	O
the	O
rats	O
were	O
divided	O
into	O
Diabetic	O
nephropathy	I:C0011881
group	O
,	O
Diabetic	O
nephropathy	I:C0011881
group	O
receiving	O
Telmisartan	O
or	O
Sildenafil	O
or	O
Telmisartan	O
Sildenafil	B:C0529793
combination	O
.	O

Thereafter	O
,	O
the	O
rats	O
were	O
divided	O
into	O
Diabetic	O
nephropathy	I:C0011881
group	O
,	O
Diabetic	O
nephropathy	I:C0011881
group	O
receiving	O
Telmisartan	O
or	O
Sildenafil	O
or	O
Telmisartan	O
Sildenafil	O
combination	B:C0013162
.	O

After	O
the	O
specified	O
treatment	O
period	O
,	O
urine	B:C1610733
samples	I:C1610733
were	O
collected	O
(	O
using	O
metabolic	O
cages	O
)	O
to	O
measure	O
proteinuria	O
,	O
animals	O
were	O
then	O
euthanized	O
,	O
blood	O
and	O
tissue	O
samples	I:C1292533
were	O
collected	O
for	O
measurement	O
of	I:C0392201
Blood	I:C0392201
glucose	I:C0392201
,	O
BUN	O
,	O
S.Cr	O
,	O
LDL	O
,	O
NO	O
,	O
TGF	O
-	I:C3889969
β1	I:C3889969
,	O
IL	O
-	I:C3815172
1	I:C3815172
β	I:C3815172
,	O
AGEPs	O
,	O
and	O
SOD	O
.	O

After	O
the	O
specified	O
treatment	O
period	O
,	O
urine	O
samples	I:C1610733
were	O
collected	O
(	O
using	O
metabolic	O
cages	O
)	O
to	O
measure	O
proteinuria	B:C0033687
,	O
animals	O
were	O
then	O
euthanized	O
,	O
blood	O
and	O
tissue	O
samples	I:C1292533
were	O
collected	O
for	O
measurement	O
of	I:C0392201
Blood	I:C0392201
glucose	I:C0392201
,	O
BUN	O
,	O
S.Cr	O
,	O
LDL	O
,	O
NO	O
,	O
TGF	O
-	I:C3889969
β1	I:C3889969
,	O
IL	O
-	I:C3815172
1	I:C3815172
β	I:C3815172
,	O
AGEPs	O
,	O
and	O
SOD	O
.	O

After	O
the	O
specified	O
treatment	O
period	O
,	O
urine	O
samples	I:C1610733
were	O
collected	O
(	O
using	O
metabolic	O
cages	O
)	O
to	O
measure	O
proteinuria	O
,	O
animals	B:C0003062
were	O
then	O
euthanized	O
,	O
blood	O
and	O
tissue	O
samples	I:C1292533
were	O
collected	O
for	O
measurement	O
of	I:C0392201
Blood	I:C0392201
glucose	I:C0392201
,	O
BUN	O
,	O
S.Cr	O
,	O
LDL	O
,	O
NO	O
,	O
TGF	O
-	I:C3889969
β1	I:C3889969
,	O
IL	O
-	I:C3815172
1	I:C3815172
β	I:C3815172
,	O
AGEPs	O
,	O
and	O
SOD	O
.	O

After	O
the	O
specified	O
treatment	O
period	O
,	O
urine	O
samples	I:C1610733
were	O
collected	O
(	O
using	O
metabolic	O
cages	O
)	O
to	O
measure	O
proteinuria	O
,	O
animals	O
were	O
then	O
euthanized	O
,	O
blood	B:C0178913
and	O
tissue	O
samples	I:C1292533
were	O
collected	O
for	O
measurement	O
of	I:C0392201
Blood	I:C0392201
glucose	I:C0392201
,	O
BUN	O
,	O
S.Cr	O
,	O
LDL	O
,	O
NO	O
,	O
TGF	O
-	I:C3889969
β1	I:C3889969
,	O
IL	O
-	I:C3815172
1	I:C3815172
β	I:C3815172
,	O
AGEPs	O
,	O
and	O
SOD	O
.	O

After	O
the	O
specified	O
treatment	O
period	O
,	O
urine	O
samples	I:C1610733
were	O
collected	O
(	O
using	O
metabolic	O
cages	O
)	O
to	O
measure	O
proteinuria	O
,	O
animals	O
were	O
then	O
euthanized	O
,	O
blood	O
and	O
tissue	B:C1292533
samples	I:C1292533
were	O
collected	O
for	O
measurement	O
of	I:C0392201
Blood	I:C0392201
glucose	I:C0392201
,	O
BUN	O
,	O
S.Cr	O
,	O
LDL	O
,	O
NO	O
,	O
TGF	O
-	I:C3889969
β1	I:C3889969
,	O
IL	O
-	I:C3815172
1	I:C3815172
β	I:C3815172
,	O
AGEPs	O
,	O
and	O
SOD	O
.	O

After	O
the	O
specified	O
treatment	O
period	O
,	O
urine	O
samples	I:C1610733
were	O
collected	O
(	O
using	O
metabolic	O
cages	O
)	O
to	O
measure	O
proteinuria	O
,	O
animals	O
were	O
then	O
euthanized	O
,	O
blood	O
and	O
tissue	O
samples	I:C1292533
were	O
collected	O
for	O
measurement	B:C0392201
of	I:C0392201
Blood	I:C0392201
glucose	I:C0392201
,	O
BUN	O
,	O
S.Cr	O
,	O
LDL	O
,	O
NO	O
,	O
TGF	O
-	I:C3889969
β1	I:C3889969
,	O
IL	O
-	I:C3815172
1	I:C3815172
β	I:C3815172
,	O
AGEPs	O
,	O
and	O
SOD	O
.	O

After	O
the	O
specified	O
treatment	O
period	O
,	O
urine	O
samples	I:C1610733
were	O
collected	O
(	O
using	O
metabolic	O
cages	O
)	O
to	O
measure	O
proteinuria	O
,	O
animals	O
were	O
then	O
euthanized	O
,	O
blood	O
and	O
tissue	O
samples	I:C1292533
were	O
collected	O
for	O
measurement	O
of	I:C0392201
Blood	I:C0392201
glucose	I:C0392201
,	O
BUN	B:C0005845
,	O
S.Cr	O
,	O
LDL	O
,	O
NO	O
,	O
TGF	O
-	I:C3889969
β1	I:C3889969
,	O
IL	O
-	I:C3815172
1	I:C3815172
β	I:C3815172
,	O
AGEPs	O
,	O
and	O
SOD	O
.	O

After	O
the	O
specified	O
treatment	O
period	O
,	O
urine	O
samples	I:C1610733
were	O
collected	O
(	O
using	O
metabolic	O
cages	O
)	O
to	O
measure	O
proteinuria	O
,	O
animals	O
were	O
then	O
euthanized	O
,	O
blood	O
and	O
tissue	O
samples	I:C1292533
were	O
collected	O
for	O
measurement	O
of	I:C0392201
Blood	I:C0392201
glucose	I:C0392201
,	O
BUN	O
,	O
S.Cr	B:C0201976
,	O
LDL	O
,	O
NO	O
,	O
TGF	O
-	I:C3889969
β1	I:C3889969
,	O
IL	O
-	I:C3815172
1	I:C3815172
β	I:C3815172
,	O
AGEPs	O
,	O
and	O
SOD	O
.	O

After	O
the	O
specified	O
treatment	O
period	O
,	O
urine	O
samples	I:C1610733
were	O
collected	O
(	O
using	O
metabolic	O
cages	O
)	O
to	O
measure	O
proteinuria	O
,	O
animals	O
were	O
then	O
euthanized	O
,	O
blood	O
and	O
tissue	O
samples	I:C1292533
were	O
collected	O
for	O
measurement	O
of	I:C0392201
Blood	I:C0392201
glucose	I:C0392201
,	O
BUN	O
,	O
S.Cr	O
,	O
LDL	B:C0202117
,	O
NO	O
,	O
TGF	O
-	I:C3889969
β1	I:C3889969
,	O
IL	O
-	I:C3815172
1	I:C3815172
β	I:C3815172
,	O
AGEPs	O
,	O
and	O
SOD	O
.	O

After	O
the	O
specified	O
treatment	O
period	O
,	O
urine	O
samples	I:C1610733
were	O
collected	O
(	O
using	O
metabolic	O
cages	O
)	O
to	O
measure	O
proteinuria	O
,	O
animals	O
were	O
then	O
euthanized	O
,	O
blood	O
and	O
tissue	O
samples	I:C1292533
were	O
collected	O
for	O
measurement	O
of	I:C0392201
Blood	I:C0392201
glucose	I:C0392201
,	O
BUN	O
,	O
S.Cr	O
,	O
LDL	O
,	O
NO	B:C3810607
,	O
TGF	O
-	I:C3889969
β1	I:C3889969
,	O
IL	O
-	I:C3815172
1	I:C3815172
β	I:C3815172
,	O
AGEPs	O
,	O
and	O
SOD	O
.	O

After	O
the	O
specified	O
treatment	O
period	O
,	O
urine	O
samples	I:C1610733
were	O
collected	O
(	O
using	O
metabolic	O
cages	O
)	O
to	O
measure	O
proteinuria	O
,	O
animals	O
were	O
then	O
euthanized	O
,	O
blood	O
and	O
tissue	O
samples	I:C1292533
were	O
collected	O
for	O
measurement	O
of	I:C0392201
Blood	I:C0392201
glucose	I:C0392201
,	O
BUN	O
,	O
S.Cr	O
,	O
LDL	O
,	O
NO	O
,	O
TGF	B:C3889969
-	I:C3889969
β1	I:C3889969
,	O
IL	O
-	I:C3815172
1	I:C3815172
β	I:C3815172
,	O
AGEPs	O
,	O
and	O
SOD	O
.	O

After	O
the	O
specified	O
treatment	O
period	O
,	O
urine	O
samples	I:C1610733
were	O
collected	O
(	O
using	O
metabolic	O
cages	O
)	O
to	O
measure	O
proteinuria	O
,	O
animals	O
were	O
then	O
euthanized	O
,	O
blood	O
and	O
tissue	O
samples	I:C1292533
were	O
collected	O
for	O
measurement	O
of	I:C0392201
Blood	I:C0392201
glucose	I:C0392201
,	O
BUN	O
,	O
S.Cr	O
,	O
LDL	O
,	O
NO	O
,	O
TGF	O
-	I:C3889969
β1	I:C3889969
,	O
IL	B:C3815172
-	I:C3815172
1	I:C3815172
β	I:C3815172
,	O
AGEPs	O
,	O
and	O
SOD	O
.	O

After	O
the	O
specified	O
treatment	O
period	O
,	O
urine	O
samples	I:C1610733
were	O
collected	O
(	O
using	O
metabolic	O
cages	O
)	O
to	O
measure	O
proteinuria	O
,	O
animals	O
were	O
then	O
euthanized	O
,	O
blood	O
and	O
tissue	O
samples	I:C1292533
were	O
collected	O
for	O
measurement	O
of	I:C0392201
Blood	I:C0392201
glucose	I:C0392201
,	O
BUN	O
,	O
S.Cr	O
,	O
LDL	O
,	O
NO	O
,	O
TGF	O
-	I:C3889969
β1	I:C3889969
,	O
IL	O
-	I:C3815172
1	I:C3815172
β	I:C3815172
,	O
AGEPs	B:C0022885
,	O
and	O
SOD	O
.	O

After	O
the	O
specified	O
treatment	O
period	O
,	O
urine	O
samples	I:C1610733
were	O
collected	O
(	O
using	O
metabolic	O
cages	O
)	O
to	O
measure	O
proteinuria	O
,	O
animals	O
were	O
then	O
euthanized	O
,	O
blood	O
and	O
tissue	O
samples	I:C1292533
were	O
collected	O
for	O
measurement	O
of	I:C0392201
Blood	I:C0392201
glucose	I:C0392201
,	O
BUN	O
,	O
S.Cr	O
,	O
LDL	O
,	O
NO	O
,	O
TGF	O
-	I:C3889969
β1	I:C3889969
,	O
IL	O
-	I:C3815172
1	I:C3815172
β	I:C3815172
,	O
AGEPs	O
,	O
and	O
SOD	B:C0022885
.	O

The	O
combination	B:C0013218
therapy	I:C0013218
showed	O
significant	O
decrease	O
in	O
BUN	O
,	O
S.Cr	O
,	O
LDL	O
,	O
TGF	O
-	I:C1704256
β1	I:C1704256
,	O
IL	O
-	I:C0021753
1	I:C0021753
β	I:C0021753
,	O
Proteinuria	O
and	O
AGEPs	O
and	O
significant	O
increase	O
in	O
SOD	O
and	O
NO	O
.	O

The	O
combination	O
therapy	I:C0013218
showed	O
significant	O
decrease	O
in	O
BUN	B:C0600137
,	O
S.Cr	O
,	O
LDL	O
,	O
TGF	O
-	I:C1704256
β1	I:C1704256
,	O
IL	O
-	I:C0021753
1	I:C0021753
β	I:C0021753
,	O
Proteinuria	O
and	O
AGEPs	O
and	O
significant	O
increase	O
in	O
SOD	O
and	O
NO	O
.	O

The	O
combination	O
therapy	I:C0013218
showed	O
significant	O
decrease	O
in	O
BUN	O
,	O
S.Cr	B:C0010294
,	O
LDL	O
,	O
TGF	O
-	I:C1704256
β1	I:C1704256
,	O
IL	O
-	I:C0021753
1	I:C0021753
β	I:C0021753
,	O
Proteinuria	O
and	O
AGEPs	O
and	O
significant	O
increase	O
in	O
SOD	O
and	O
NO	O
.	O

The	O
combination	O
therapy	I:C0013218
showed	O
significant	O
decrease	O
in	O
BUN	O
,	O
S.Cr	O
,	O
LDL	B:C0023823
,	O
TGF	O
-	I:C1704256
β1	I:C1704256
,	O
IL	O
-	I:C0021753
1	I:C0021753
β	I:C0021753
,	O
Proteinuria	O
and	O
AGEPs	O
and	O
significant	O
increase	O
in	O
SOD	O
and	O
NO	O
.	O

The	O
combination	O
therapy	I:C0013218
showed	O
significant	O
decrease	O
in	O
BUN	O
,	O
S.Cr	O
,	O
LDL	O
,	O
TGF	B:C1704256
-	I:C1704256
β1	I:C1704256
,	O
IL	O
-	I:C0021753
1	I:C0021753
β	I:C0021753
,	O
Proteinuria	O
and	O
AGEPs	O
and	O
significant	O
increase	O
in	O
SOD	O
and	O
NO	O
.	O

The	O
combination	O
therapy	I:C0013218
showed	O
significant	O
decrease	O
in	O
BUN	O
,	O
S.Cr	O
,	O
LDL	O
,	O
TGF	O
-	I:C1704256
β1	I:C1704256
,	O
IL	B:C0021753
-	I:C0021753
1	I:C0021753
β	I:C0021753
,	O
Proteinuria	O
and	O
AGEPs	O
and	O
significant	O
increase	O
in	O
SOD	O
and	O
NO	O
.	O

The	O
combination	O
therapy	I:C0013218
showed	O
significant	O
decrease	O
in	O
BUN	O
,	O
S.Cr	O
,	O
LDL	O
,	O
TGF	O
-	I:C1704256
β1	I:C1704256
,	O
IL	O
-	I:C0021753
1	I:C0021753
β	I:C0021753
,	O
Proteinuria	B:C0033687
and	O
AGEPs	O
and	O
significant	O
increase	O
in	O
SOD	O
and	O
NO	O
.	O

The	O
combination	O
therapy	I:C0013218
showed	O
significant	O
decrease	O
in	O
BUN	O
,	O
S.Cr	O
,	O
LDL	O
,	O
TGF	O
-	I:C1704256
β1	I:C1704256
,	O
IL	O
-	I:C0021753
1	I:C0021753
β	I:C0021753
,	O
Proteinuria	O
and	O
AGEPs	B:C0162574
and	O
significant	O
increase	O
in	O
SOD	O
and	O
NO	O
.	O

The	O
combination	O
therapy	I:C0013218
showed	O
significant	O
decrease	O
in	O
BUN	O
,	O
S.Cr	O
,	O
LDL	O
,	O
TGF	O
-	I:C1704256
β1	I:C1704256
,	O
IL	O
-	I:C0021753
1	I:C0021753
β	I:C0021753
,	O
Proteinuria	O
and	O
AGEPs	O
and	O
significant	O
increase	O
in	O
SOD	B:C0038838
and	O
NO	O
.	O

The	O
combination	O
therapy	I:C0013218
showed	O
significant	O
decrease	O
in	O
BUN	O
,	O
S.Cr	O
,	O
LDL	O
,	O
TGF	O
-	I:C1704256
β1	I:C1704256
,	O
IL	O
-	I:C0021753
1	I:C0021753
β	I:C0021753
,	O
Proteinuria	O
and	O
AGEPs	O
and	O
significant	O
increase	O
in	O
SOD	O
and	O
NO	B:C0028128
.	O

The	O
findings	O
showed	O
that	O
combination	B:C0013218
therapy	I:C0013218
was	O
able	O
to	O
ameliorate	O
Diabetic	O
nephropathy	I:C0011881
and	O
that	O
the	O
effects	O
were	O
superior	O
to	O
the	O
single	O
drugs	O
alone	O
.	O

The	O
findings	O
showed	O
that	O
combination	O
therapy	I:C0013218
was	O
able	O
to	O
ameliorate	O
Diabetic	B:C0011881
nephropathy	I:C0011881
and	O
that	O
the	O
effects	O
were	O
superior	O
to	O
the	O
single	O
drugs	O
alone	O
.	O

The	O
findings	O
showed	O
that	O
combination	O
therapy	I:C0013218
was	O
able	O
to	O
ameliorate	O
Diabetic	O
nephropathy	I:C0011881
and	O
that	O
the	O
effects	O
were	O
superior	O
to	O
the	O
single	O
drugs	B:C0013227
alone	O
.	O

